Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
| ▸ | SGMS1 | Q86VZ5 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | MMP2 | P08253 | 2/20 | 0.61 |
| ▸ | MMP9 | P14780 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.56 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19334535 | 0.90 | ALDH1A1 (0.67) | KMT2AMEN1ALDH1A1USP2SGMS1 | |
| SCHEMBL19334435 | 0.88 | RAB9A (0.73) | KMT2AMEN1ALDH1A1SGMS1MMP2 | |
| SCHEMBL13401893 | 0.87 | ALDH1A1 (0.88) | KMT2AMEN1ALDH1A1USP2SMN1; SMN2 | |
| SCHEMBL19334330 | 0.87 | USP2 (0.67) | KMT2AMEN1ALDH1A1USP2SGMS1 | |
| SCHEMBL13401888 | 0.87 | POLB (0.70) | KMT2AMEN1ALDH1A1USP2SGMS1 | |
| SCHEMBL14142894 | 0.87 | ALDH1A1 (0.87) | KMT2AALDH1A1USP2SMN1; SMN2RAB9A | |
| SCHEMBL13401890 | 0.86 | KDM4E (0.62) | KMT2AMEN1ALDH1A1USP2SGMS1 | |
| SCHEMBL13401884 | 0.82 | ALDH1A1 (0.79) | ALDH1A1USP2SGMS1RAB9A | |
| SCHEMBL7417828 | 0.80 | MEP1B (0.72) | KMT2AMEN1ALDH1A1KDM4EMMP2 | |
| SCHEMBL2831966 | 0.80 | CYP19A1 (0.78) | ALDH1A1SMN1; SMN2KDM4EL3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9757375-B2 | Compounds that inhibit human DNA ligases and methods of treating cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-09-12 | — | — | US | disclosed |
| US-8445537-B2 | Compounds that inhibit human DNA ligases and methods of treating cancer | STC.UNM (US) | 2013-05-21 | — | — | US | disclosed |
| US-20100099683-A1 | COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099683-A1 | COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER | LIG1, LIG4, LIG3 | KMT2A 1608/4885MEN1 2792/4885ALDH1A1 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.